Abstract and Introduction
Osteosarcoma is the most common primary bone sarcoma and affects both children and adults. The cornerstone of treatment for patients with localized and oligometastatic disease remains neoadjuvant chemotherapy, surgical resection of all sites of disease, followed by adjuvant chemotherapy. This approach is associated with up to an 80% 5-year survival. However, survival of patients with metastatic disease remains poor, and overall, osteosarcoma remains a challenging disease to treat. Advances in the understanding of molecular drivers of the disease, identification of poor prognostic factors, development of risk-stratified treatment protocols, successful completion of large collaborative trials, and surgical advances have laid the ground work for progress. Advances in computer navigation, implant design, and surgical techniques have allowed surgeons to improve patients' physical functional without sacrificing oncologic outcomes. Future goals include identifying effective risk stratification algorithms which minimize patient toxicity while maximizing oncologic outcomes and continuing to improve the durability, function, and patient acceptance of oncologic reconstructions.
Osteosarcoma, the most common primary bone sarcoma, is a heterogenous disease regarding patient age, histologic subtypes, treatment approaches, and prognosis. Recent international collaboration between osteosarcoma study groups has aimed to improve our understanding of osteosarcoma, define prognostic factors, and develop risk-stratified treatment protocols. Emerging therapies, technological advances in imaging and surgical techniques, and improved endoprosthetic designs aim to optimize oncologic and functional outcomes in patients with osteosarcoma.
J Am Acad Orthop Surg. 2021;29(20):e993-e1004. © 2021 American Academy of Orthopaedic Surgeons